ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2022

1:00PM-3:00PM: Abstract Number: 1977

Tc99m Tilmanocept Imaging Predicts Clinical Response in Rheumatoid Arthritis Patients Beginning New Anti-TNFα Therapy

RA – Diagnosis, Manifestations, and Outcomes Poster IV

1:00PM-3:00PM: Abstract Number: L07

Telitacicept, a Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Systemic Lupus Erythematosus (SLE): Results of a Phase 3 Study

(L07–L17) Late-Breaking Abstract Poster

1:00PM-3:00PM: Abstract Number: 1753

Temporal Trends of SLE Mortality Among Various Ethnic Categories Across the United States: 2001-to 2020 Analysis from WONDER Database

Epidemiology and Public Health Poster III

1:00PM-3:00PM: Abstract Number: 1840

The 2019 ACR/EULAR Classification Criteria for IgG4-Related Disease Perform Lower Than Expected: Data from a Norwegian Cohort

Miscellaneous Rheumatic and Inflammatory Diseases Poster III

1:00PM-3:00PM: Abstract Number: 1913

The Association of Radiographic Chondrocalcinosis with Localized Structural Outcomes in Knee OA: The Multicenter Osteoarthritis Study

Osteoarthritis – Clinical Poster

1:00PM-3:00PM: Abstract Number: 1985

The BEGIN Study: A Double-blind, Multi-center, Two-part, Randomized, Placebo-controlled Study of the Safety, Tolerability, and Efficacy of 4 Weeks of Treatment with AP1189 in Early Rheumatoid Arthritis (RA) Patients with Active Joint Disease

RA – Treatment Poster IV

1:00PM-3:00PM: Abstract Number: 1711

The Cellular Basis for Type I Interferon Production Following Ultraviolet Light Stimulated Cyclic-GMP-AMP Synthase Activation in the Skin

SLE – Animal Models Poster

1:00PM-3:00PM: Abstract Number: 1714

The Circadian Clock Gene Bmal1 Negatively Regulates Autoantibody Production in SLE

SLE – Animal Models Poster

1:00PM-3:00PM: Abstract Number: 1771

The Effectiveness of a Treat-to-target Strategy in Rheumatic Diseases: A Systematic Literature Review and Meta-analysis

Epidemiology and Public Health Poster III

1:00PM-3:00PM: Abstract Number: 1890

The Efficacy of Intra-articular Triamcinolone Acetonide 10 mg vs. 40 mg in Patients with Knee Osteoarthritis: a Non-inferiority, Randomized, Controlled, Double-blind, Multicenter Study

Osteoarthritis – Clinical Poster

1:00PM-3:00PM: Abstract Number: 1722

The ERβ Agonist, WT-IV-012, Suppresses the Inflammatory Response in Systemic Lupus Erythematosus

SLE – Animal Models Poster

1:00PM-3:00PM: Abstract Number: 1787

The Impact of Topically Applied pH Modulator on Acute Inflammatory Pain, Serum Calcium, and C-Reactive Protein (CRP) During an Acute Gout Flare – a Phase 2a Randomized, Double-Blind, Placebo-Controlled Study

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 2089

The Implication of Skin Involvement on Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE) Patients

SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

1:00PM-3:00PM: Abstract Number: 2073

The Incidence of COVID-19 Infection in an SLE Cohort, and Its Association with Immunosuppressants, SLE Disease Activity, Vaccination Status, and COVID-19 Antibodies

SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

1:00PM-3:00PM: Abstract Number: 1958

The Increased Risk of Staphylococcus Aureus Bacteremia in Rheumatoid Arthritis – What Is the Impact of Glucocorticoids, Biologic Disease-Modifying Anti-Rheumatic Drugs and Disease Activity: A Danish Nationwide Nested Case-Control Study in the DANBIO Registry

RA – Diagnosis, Manifestations, and Outcomes Poster IV

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].